title: Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer.
abstract: OBJECTIVE
  A phase I study was conducted to determine the maximum-tolerated dose (MTD) of a 14-day continuous infusion of etoposide, and to evaluate the pharmacokinetics in patients with lung cancer.
  
  
  METHODS
  Etoposide was administered continuously through a central venous catheter using a pump. The starting dose level was 300 mg/m2 over 14 days, with dose escalations of 100 mg/m2 over 14 days until unacceptable toxicities occurred. Pharmacokinetic studies were performed in all patients.
  
  
  RESULTS
  Twenty-one patients, 20 with non-small-cell lung cancer and one with refractory small-cell lung cancer, received 37 courses. No World Health Organization (WHO) grade III or greater toxicity occurred at doses up to 400 mg/m2 over 14 days. At 700 mg/m2 over 14 days, all four patients experienced grade III or IV leukocytopenia, and two developed grade III stomatitis. No cumulative toxicity was observed. A steady concentration of etoposide was achieved 24 hours after the start of chemotherapy, and it was significantly correlated with surviving fractions of leukocytes (r = -.64, P = .001) and platelets (r = -.68, P < .001). The leukocyte count at the termination of chemotherapy predicted the nadir count (r = .93, P < .001).
  
  
  CONCLUSIONS
  Steady blood levels of etoposide were maintained for prolonged periods, during 14-day continuous infusions. Leukocytopenia and stomatitis were dose-limiting. Nadir counts and surviving fractions of leukocytes were predicted by the leukocyte count at the end of chemotherapy and the concentration of etoposide, respectively. The recommended dose for phase II trials is 600 mg/m2 over 14 days.
authors.affiliation: Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital.
authors.forename: H
authors.initials: H
authors.lastname: Minami
authors.forename: K
authors.initials: K
authors.lastname: Shimokata
authors.forename: H
authors.initials: H
authors.lastname: Saka
authors.forename: H
authors.initials: H
authors.lastname: Saito
authors.forename: Y
authors.initials: Y
authors.lastname: Ando
authors.forename: K
authors.initials: K
authors.lastname: Senda
authors.forename: F
authors.initials: F
authors.lastname: Nomura
authors.forename: S
authors.initials: S
authors.lastname: Sakai
mesh_terms: D000328:Adult; D000368:Aged; D002405:Catheterization, Central Venous; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007260:Infusion Pumps; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged
chemical_list: D005047:Etoposide